Filing Flows

Filing Flows › Companies › Pure Bioscience › Cash flow

Pure Bioscience cash flow, quarter by quarter

Latest: Q4 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$414K in Q4 FY26

Operating cash flow−$414K
Free cash flow−$414K
Cash conversion cycle-136 days

Analysis

In Q4 FY26, Pure Bioscience generated −$414K of operating cash flow. That is $42K more than in Q4 FY25 (−$456K).

Operating cash flow was −$414K against net income of −$610K. The largest differences: receivables −$92K, payables +$90K, stock-based pay +$50K.

Its cash conversion cycle was -136 days (receivables 40 + inventory 67 − payables 243): suppliers fund its working capital.

Free cash flow

Pure Bioscience: free cash flow by quarterPure Bioscience: free cash flow by quarter−$503KQ1 FY25−$544KQ2 FY25−$512KQ3 FY25−$456KQ4 FY25−$250KQ1 FY26−$606KQ2 FY26−$468KQ3 FY26−$414KQ4 FY26
Operating cash flow less capital spending.
Pure Bioscience: operating cash flow against capital spendingPure Bioscience: operating cash flow against capital spendingOperating cash flowCapital spending−$503K$0Q1 FY25−$544K$0Q2 FY25−$512K$0Q3 FY25−$456K$0Q4 FY25−$250K$0Q1 FY26−$606K$0Q2 FY26−$468K$0Q3 FY26−$414K$0Q4 FY26
Latest (Q4 FY26): Operating cash flow −$414K, Capital spending $0.

Capital allocation, year by year

Pure Bioscience: where the cash came from (up) and went (down), by fiscal yearPure Bioscience: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY22: Operating cash flow −$2.4MFY22: Shares issued $3.5MFY22: Capital spending −$81K$3.5MFY22FY23: Operating cash flow −$3.3MFY23: Net borrowing $1.0MFY23: Capital spending −$33K$1.0MFY23FY24: Operating cash flow −$2.5MFY24: Net borrowing $1.8M$1.8MFY24FY25: Operating cash flow −$2.0MFY25FY26: Operating cash flow −$1.7MFY26
Over these 5 years operating cash flow totalled −$12.0M; the largest uses were operating cash flow ($12.0M) and capital spending ($114K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$569K
Debt$6.6M
Net debt$6.0M
Due within a year$3.4M
Cash runway4 months

Pure Bioscience is burning cash: its operations consume cash, a free cash flow of −$1.7M a year at the current rate against $569K of cash and investments: a runway of about 4 months; $3.4M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Pure Bioscience: debt maturities by year (FY26)Pure Bioscience: debt maturities by year (FY26)$3.4MYear 1$2.2MYear 2$1.0MYear 3
Principal due in each year as disclosed in the annual report, against $569K of cash and investments now.

Where the cash came from and went

Pure Bioscience: sources (+) and uses (−) of cash, Q4 FY26Pure Bioscience: sources (+) and uses (−) of cash, Q4 FY26Operating cash flow−$414KCash drawn (+) / kept (−)$414K

From profit to cash

Pure Bioscience: net income to operating cash flow, Q4 FY26Pure Bioscience: net income to operating cash flow, Q4 FY26Net income−$610KDepreciation & amortization$1KStock-based pay$50KReceivables−$92KInventory$39KPayables$90KPrepaid and other assets$3KOperating cash flow−$414K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q4 FY264067243-136
Q3 FY264389279-146
Q2 FY2667107368-194
Q1 FY265667297-173
Q4 FY254642246-158
Q3 FY254244321-234
Q2 FY256541398-292
Q1 FY255525263-182

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q4 FY26−$414K$414K−$414K
Q3 FY26−$468K−$785K−$468K
Q2 FY26−$606K$236K−$606K
Q1 FY26−$250K−$100K−$250K
Q4 FY25−$456K$206K−$456K
Q3 FY25−$512K−$338K−$512K
Q2 FY25−$544K$144K−$544K
Q1 FY25−$503K$3K−$503K

Pure Bioscience: income statement and cash flow

Pure Bioscience, Q4 FY26: revenue $659K (-14% year over year), operating margin -76.3%. The chart follows the revenue to costs, profit and cash.

Pure Bioscience: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.